全文获取类型
收费全文 | 6489篇 |
免费 | 407篇 |
国内免费 | 32篇 |
专业分类
耳鼻咽喉 | 73篇 |
儿科学 | 137篇 |
妇产科学 | 73篇 |
基础医学 | 847篇 |
口腔科学 | 172篇 |
临床医学 | 476篇 |
内科学 | 1477篇 |
皮肤病学 | 266篇 |
神经病学 | 411篇 |
特种医学 | 223篇 |
外科学 | 1178篇 |
综合类 | 19篇 |
预防医学 | 158篇 |
眼科学 | 76篇 |
药学 | 583篇 |
中国医学 | 6篇 |
肿瘤学 | 753篇 |
出版年
2023年 | 39篇 |
2022年 | 61篇 |
2021年 | 120篇 |
2020年 | 51篇 |
2019年 | 115篇 |
2018年 | 124篇 |
2017年 | 107篇 |
2016年 | 117篇 |
2015年 | 140篇 |
2014年 | 146篇 |
2013年 | 213篇 |
2012年 | 329篇 |
2011年 | 321篇 |
2010年 | 217篇 |
2009年 | 183篇 |
2008年 | 346篇 |
2007年 | 353篇 |
2006年 | 399篇 |
2005年 | 455篇 |
2004年 | 427篇 |
2003年 | 381篇 |
2002年 | 415篇 |
2001年 | 133篇 |
2000年 | 122篇 |
1999年 | 161篇 |
1998年 | 144篇 |
1997年 | 104篇 |
1996年 | 100篇 |
1995年 | 73篇 |
1994年 | 55篇 |
1993年 | 61篇 |
1992年 | 74篇 |
1991年 | 82篇 |
1990年 | 74篇 |
1989年 | 57篇 |
1988年 | 89篇 |
1987年 | 84篇 |
1986年 | 74篇 |
1985年 | 52篇 |
1984年 | 45篇 |
1983年 | 36篇 |
1982年 | 20篇 |
1981年 | 28篇 |
1980年 | 14篇 |
1979年 | 24篇 |
1978年 | 25篇 |
1971年 | 12篇 |
1969年 | 16篇 |
1968年 | 14篇 |
1967年 | 12篇 |
排序方式: 共有6928条查询结果,搜索用时 31 毫秒
101.
102.
Fujii K; Fukutomi T; Tsuda H; Akashi-Tanaka S; Nanasawa T; Kanai Y; Muramatsu Y 《Japanese journal of clinical oncology》1998,28(1):47-49
A 44-year-old woman presented with a right huge axillary mass. Both
mammography and ultrasonography revealed a primary cancer of 2.8 cm maximum
diameter in the right breast and metastases in the axillary lymph nodes,
both being confirmed by aspiration cytology as ductal carcinoma. Right
standard radical mastectomy with level III axillary lymph node dissection
was carried out. Pathologically, the tumor was diagnosed as ductal
carcinoma in situ with microinvasion (DCISM), histologic grade 3. The area
of stromal invasion measured 1 mm at its widest point. Sixteen of the 17
resected axillary lymph nodes contained metastases, including six level III
lymph nodes. Immunohistochemical studies of the tumor revealed
overexpression of p53 protein, but not that of c-erbB-2 protein. The
frequency of lymph node metastases from DCISM is reported to be very low.
Therefore, the present case with extensive involvement of level III lymph
nodes was unusual.
相似文献
103.
Akifumi Kuwabara Hidenobu Watanabe Yoichi Ajioka Kazuhiro Yasuda Hidetoshi Saito Keiji Matsuda Hiroshi Kijima Katuyoshi Hatakeyama 《Cancer science》1998,89(1):40-46
The aim of this study was to clarify whether or not the status of gene alteration is heterogeneous in intramucosal carcinoma and homogeneous within invasive carcinoma. We selected 10 colorectal carcinoma cases (1 mucosal, 5 submucosal and 4 advanced carcinomas including 2 cases with lymph node metastasis) and analyzed the p53 gene sequence. Six colorectal cancers in this study showed heterogeneity in p53 mutations in cells from the intramucosal part. In the invasive part of a carcinoma, p53 mutation status was homogeneous intratumorally in all cases. These data indicate that, in regard to p53 gene alterations, colorectal cancers can be composed of various subclones when limited to the mucosa, but clonal selection occurs when one of these subclones commences invasion to the submucosa, generating a monoclonal invasive carcinoma. 相似文献
104.
Genetic Alterations of Mixed Hyperplastic Adenomatous Polyps in the Colon and Rectum 总被引:1,自引:2,他引:1
Hiroyuki Uchida Hiroshi Ando Keiji Maruyama Hiroshi Kobayashi Hiroshi Toda Hiroshi Ogawa Takachika Ozawa Yasuhide Matsuda Haruhiko Sugimura Takashi Kanno Shozo Baba 《Cancer science》1998,89(3):299-306
Some mixed hyperplastic adenomatous polyps (MHAPs) contain dysplastic lesions or even carcinomas. These polyps are considered to be different from ordinary hyperplastic polyps and may have a preneoplastic potential. We investigated APC and K- ras mutations in MHAPs of the colon and rectum, and also in colorectal adenomas and hyperplastic polyps to identify molecular differences between MHAPs, adenomas and hyperplastic polyps, using direct sequencing of mutation cluster regions (MCR) in APC and K- ras . No APC mutations were identified in 12 MHAPs and 8 hyperplastic polyps, whereas 10 of 27 (37.0%) adenomas showed somatic mutations. K- ras mutations were identified in one of 12 (8.3%) MHAPs, one of 8 (12.5%) hyperplastic polyps, and 10 of 27 (37.0%) adenomas. p53 mutation was found in a carcinoma arising in an MHAP. Mutations other than APC mutations may play a role in the development of MHAPs. 相似文献
105.
K. Aridome S. Takao T. Kaname K. Kadomatsu S. Natsugoe F. Kijima T. Aikou T. Muramatsu 《British journal of cancer》1998,78(4):472-477
Midkine (MK) is a growth factor identified as a product of a retinoic acid-responsive gene. A truncated form of MK mRNA, which lacks a sequence encoding the N-terminally located domain, was recently found in cancer cells. We investigated the expression of the truncated MK mRNA in specimens of 47 surgically removed human gastrointestinal organs using polymerase chain reaction. Truncated MK was not detected in all of the 46 corresponding non-cancerous regions. On the other hand, this short MK mRNA was expressed in the primary tumours in 12 of 16 gastric cancers, 8 of 13 colorectal carcinomas, five of nine hepatocellular carcinomas, two of two oesophageal carcinomas and one ampullary duodenal cancer. In addition, truncated MK was detectable in all of the 14 lymph node metastases but in none of three metastatic sites in the liver, suggesting that truncated MK mRNA could become a good marker of nodal metastases in gastrointestinal tract. 相似文献
106.
Ozawa K Fan DS Shen Y Muramatsu S Fujimoto K Ikeguchi K Ogawa M Urabe M Kume A Nakano I 《Journal of neural transmission. Supplementum》2000,(58):181-191
Parkinson's disease (PD) is characterized by the progressive loss of the dopaminergic neurons in the substantia nigra and a severe decrease in dopamine in the striatum. A promising approach to the gene therapy of PD is intrastriatal expression of dopamine-synthesizing enzymes [tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC)]. The most appropriate gene-delivery vehicles for neurons are adeno-associated virus (AAV) vectors, which are derived from non-pathogenic virus. Therefore, TH and AADC genes were introduced into the striatum in the lesioned side using separate AAV vectors in parkinsonian rats, and the coexpression of TH and AADC resulted in better behavioral recovery compared with TH alone. Another strategy for gene therapy of PD is the protection of dopaminergic neurons in the substantia nigra using an AAV vector containing a glial cell line-derived neurotrophic factor (GDNF) gene. Combination of dopamine-supplement gene therapy and GDNF gene therapy would be a logical approach to the treatment of PD. 相似文献
107.
Nitric oxide synthase activity and inhibition after neonatal hypoxia ischemia in the mouse brain 总被引:7,自引:0,他引:7
Muramatsu K Sheldon RA Black SM Täuber M Ferriero DM 《Brain research. Developmental brain research》2000,123(2):119-127
Despite the emergence of therapies for hypoxic-ischemic injury to the mature nervous system, there have been no proven efficacious therapies for the developing nervous system. Recent studies have shown that pharmacological blockade of neuronal nitric oxide synthase (nNOS) activity can ameliorate damage after ischemia in the mature rodent. We have previously shown that elimination of nNOS neurons, either by targeted disruption of the gene or by pharmacological depletion with intraparenchymal quisqualate, can decrease injury after hypoxia-ischemia. Using a simpler pharmacological approach, we studied the efficacy of a systemically administered NOS inhibitor, 7-nitroindazole, a relatively selective inhibitor of nNOS activity. Using multiple doses and concentrations administered after the insult, we found that there was only a trend for protection with higher doses of the drug. A significant decrease in NOS activity was seen at 18 h and 5 days in the cortex, and at 2 h and 18 h in the hippocampus after the hypoxia-ischemia. nNOS expression decreased and remained depressed for at least 18 h after the insult. When nNOS expression was normalized to MAP2 expression, a decrease was seen at 18 h in the cortex and at 2 and 18 h in the hippocampus. These data suggest that further inhibition of NOS activity at early timepoints may not provide substantial benefit. At 5 days after the insult, however, NOS activity and normalized nNOS expression returned to baseline or higher in the hippocampus, the region showing the most damage. These data suggest that delayed administration of nNOS inhibitor after hypoxic-ischemic injury might be beneficial. 相似文献
108.
109.
Hironobu Shibata Masahiro Abe Kenji Hiura Javier Wilde Keiji Moriyama Toshiaki Sano Ken-Ichi Kitazoe Toshihiro Hashimoto Shuji Ozaki Shingo Wakatsuki Shinsuke Kido Daisuke Inoue Toshio Matsumoto 《Clinical cancer research》2005,11(17):6109-6115
PURPOSE: Receptor activator of nuclear factor-kappaB ligand (RANKL) is a key mediator of osteoclastogenesis. Because certain types of tumor cells aberrantly express RANKL, and because bone destruction also develops in B-cell lymphomas of bone origin, we investigated RANKL expression and the mechanisms of osteoclastogenesis in B-lymphoid neoplasms. EXPERIMENTAL DESIGN AND RESULTS: Immunohistochemistry of bone specimens resected from patients with primary B-cell lymphoma of bone with bone destruction revealed that lymphoma cells express RANKL as well as vascular endothelial cell growth factor (VEGF). The tumor cells isolated from the bone specimens enhanced osteoclastogenesis in vitro. In contrast, B-cell lymphoma infiltrating to the bone marrow without bone destruction did not express RANKL. Both RANKL and VEGF were expressed by a portion of B-lymphoid cell lines, including Daudi and IM-9. These RANKL-expressing tumor cells enhanced osteoclastogenesis from RAW264.7 cells and human monocyte-derived preosteoclasts in the absence of stromal cells/osteoblasts in a RANKL-dependent manner. Furthermore, conditioned media from Daudi cells enhanced transmigration of preosteoclasts that was inhibited by anti-VEGF antibody, suggesting that tumor cell-derived VEGF mediates recruitment of osteoclast precursors. Moreover, cocultures of B-lymphoid cell lines with osteoclasts enhanced the growth of B-lymphoid cells. CONCLUSIONS: Some malignant B cells aberrantly express functional RANKL as well as VEGF to enhance osteoclastogenesis. The coexpression of RANKL and VEGF may also contribute to the close cellular interactions with osteoclastic cells, thereby forming a vicious cycle between osteoclastic bone destruction and tumor expansion in bone. 相似文献
110.
Keiji Inoue Takashi Karashima Satoshi Fukata Asuka Nomura Chiaki Kawada Atsushi Kurabayashi Mutsuo Furihata Yuji Ohtsuki Taro Shuin 《Clinical cancer research》2005,11(18):6669-6677
PURPOSE: Transitional cell carcinoma (TCC) of the urinary tract is a chemosensitive tumor. Most deaths from TCC of the urinary tract are caused by metastasis, which is resistant to conventional chemotherapy. Frequent sites of metastases from TCC of the urinary tract are regional lymph nodes, liver, lung, and bone. Of these distant metastases, bone metastasis is consistently resistant to cisplatin-based conventional chemotherapy. Therefore, in this study, we investigated whether or not a newly developed minodronate, YM529, could prevent osteolytic bone metastasis of human TCC and also enhance the effect of docetaxel in a bone tumor model of athymic nude mice. EXPERIMENTAL DESIGN: In the present study, we evaluated the effect of in vitro treatment with minodronate and/or docetaxel on the proliferation by cell count, the induction of apoptosis by terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) assay, and the biological activity of osteoclast by pit formation assay in human bladder cancer cell line, UMUC-14, and mouse osteoclast cells. In vivo, we examined the effect of minodronate in a bone tumor model of athymic nude mice, in which the percutaneous intraosseal injection in the tibia of UMUC-14, leads to osteolytic bone tumor, as a bone metastasis model. To examine whether or not minodronate could inhibit tumorigenicity and enhance the effect of the chemotherapeutic agent, docetaxel, we gave minodronate i.p. and/or docetaxel i.p. to nude mice 3 days after an intraosseal tumor implantation. Moreover, proliferation and the induction of apoptosis of cancer cells and osteoclasts in bone tumors were determined by immunohistochemistry and the TUNEL assay. RESULTS: In vitro: In vitro treatment with docetaxel inhibited proliferation and resorption pit-forming activity and induced apoptosis of mouse osteoclast cells and UMUC-14 cells. In vitro treatment with minodronate inhibited proliferation and activity and induced apoptosis of mouse osteoclast cells but not UMUC-14 cells. The treatment with minodronate enhanced the inhibition of proliferation and activity by docetaxel in osteoclasts. In vivo: In vivo combination therapy with docetaxel and minodronate significantly reduced the tumor incidence compared with the control (P < 0.05) and also growth of intraossal TCC in athymic nude mice compared with the control (P < 0.001), single therapy with docetaxel (P < 0.01), and minodronate (P < 0.05). Drug-induced body weight loss was not significantly different in any treatment group. Therapy with minodronate significantly enhanced inhibition of proliferation by docetaxel in osteoclasts of bone tumors compared with the control (P < 0.01), single therapy with docetaxel (P < 0.01), and minodronate (P < 0.05). CONCLUSIONS: These studies indicate that combination therapy with minodronate and docetaxel may be beneficial in patients with bone metastasis of human TCC in the urinary tract. 相似文献